UA117260C2 - Лікарський препарат з відстроченим вивільненням - Google Patents

Лікарський препарат з відстроченим вивільненням

Info

Publication number
UA117260C2
UA117260C2 UAA201605286A UAA201605286A UA117260C2 UA 117260 C2 UA117260 C2 UA 117260C2 UA A201605286 A UAA201605286 A UA A201605286A UA A201605286 A UAA201605286 A UA A201605286A UA 117260 C2 UA117260 C2 UA 117260C2
Authority
UA
Ukraine
Prior art keywords
delayed release
polymeric material
soluble polymeric
inner layer
delayed
Prior art date
Application number
UAA201605286A
Other languages
English (en)
Inventor
Феліпе Хосе Олівейра Варум
Гонсалес Роберто Карлос Браво
Томас Бузер
Абдул Васех Басіт
Ана Кристина Фрейр
Original Assignee
Тиллоттс Фарма АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиллоттс Фарма АГ filed Critical Тиллоттс Фарма АГ
Publication of UA117260C2 publication Critical patent/UA117260C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується застосування ізолюючого шару для прискорення вивільнення протизапального засобу в кишечнику суб'єкта з лікарського препарату з відстроченим вивільненням для перорального введення вказаному суб'єкту, при цьому вказаний препарат включає: ядро, що включає вказаний протизапальний засіб як лікарський засіб; вказаний ізолюючий шар, що покриває вказане ядро, де вказаний ізолюючий шар містить щонайменше один неіонний полімер, вибраний з гідроксипропілметилцелюлози (HPMC) і полівінілового спирту (PVA); і зовнішнє покриття для забезпечення вивільнення вказаного лікарського засобу в кишечнику, при цьому вказане зовнішнє покриття включає зовнішній шар і внутрішній шар, причому зовнішній шар включає ентеросолюбільний поліметакрилатний полімер, який має поріг pH при приблизно рН 5 або вище, і причому внутрішній шар включає розчинний поліметакрилатний полімер, що містить множину карбоксильних груп, щонайменше частина яких нейтралізована у формі карбоксилат-аніонів, де вказаний розчинний поліметакрилатний полімер розчинний в кишковому соку або шлунково-кишковому соку.
UAA201605286A 2013-10-29 2013-10-29 Лікарський препарат з відстроченим вивільненням UA117260C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
UA117260C2 true UA117260C2 (uk) 2018-07-10

Family

ID=49515360

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201605286A UA117260C2 (uk) 2013-10-29 2013-10-29 Лікарський препарат з відстроченим вивільненням

Country Status (25)

Country Link
US (1) US10799515B2 (uk)
EP (2) EP3062776A1 (uk)
JP (1) JP6273356B2 (uk)
KR (2) KR102174942B1 (uk)
CN (2) CN110279669B (uk)
AU (2) AU2013404367B2 (uk)
BR (2) BR122020013726B1 (uk)
CA (1) CA2923063C (uk)
CR (1) CR20160192A (uk)
CU (1) CU20160055A7 (uk)
EA (1) EA032504B1 (uk)
HK (1) HK1222547A1 (uk)
IL (2) IL244260B (uk)
MA (1) MA38847B2 (uk)
MX (1) MX2016001840A (uk)
MY (1) MY189394A (uk)
NZ (2) NZ747731A (uk)
PH (1) PH12016500307A1 (uk)
SA (2) SA114360006B1 (uk)
SG (1) SG11201600501UA (uk)
TN (1) TN2016000119A1 (uk)
TW (3) TWI680774B (uk)
UA (1) UA117260C2 (uk)
WO (1) WO2015062640A1 (uk)
ZA (1) ZA201600630B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2659881T (lt) * 2012-04-30 2018-02-12 Tillotts Pharma Ag Uždelsto atpalaidavimo vaisto forma
CA3207643A1 (en) 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
AU2018388566A1 (en) * 2017-12-21 2020-06-18 Pepsico, Inc. Multi-ingredient ephemeral beverage pod for making a beverage
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662901A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662902A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
US11730708B2 (en) 2019-12-11 2023-08-22 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (en) 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ES2198872T3 (es) 1999-12-16 2004-02-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Preparaciones farmaceuticas multiunitarias gastrorresistentes que contienen piroxicam.
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
KR20030097892A (ko) * 2001-05-25 2003-12-31 에스에스 세야쿠 가부시키 가이샤 의약 배합제
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
WO2004110345A2 (en) 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP2008543929A (ja) 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド デュロキセチンの調節放出型の投与製剤
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008117814A1 (ja) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
EP2152250B1 (en) * 2007-05-07 2019-09-04 Evonik Röhm GmbH Solid dosage forms comprising an enteric coating with accelerated drug release
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
SG10201708952TA (en) 2009-06-15 2017-12-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
AU2012305915B2 (en) 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
LT2659881T (lt) 2012-04-30 2018-02-12 Tillotts Pharma Ag Uždelsto atpalaidavimo vaisto forma
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Also Published As

Publication number Publication date
CN110279669B (zh) 2022-02-15
BR112016004863B1 (pt) 2022-09-20
CA2923063C (en) 2021-09-07
CN110279669A (zh) 2019-09-27
IL244260A0 (en) 2016-04-21
EA201690596A1 (ru) 2016-08-31
EA032504B1 (ru) 2019-06-28
SA114360006B1 (ar) 2016-11-09
MX2016001840A (es) 2016-08-11
AU2020201365B2 (en) 2021-09-16
ZA201600630B (en) 2017-05-31
KR20160077040A (ko) 2016-07-01
MY189394A (en) 2022-02-09
JP2016535030A (ja) 2016-11-10
HK1222547A1 (zh) 2017-07-07
WO2015062640A1 (en) 2015-05-07
KR102237356B1 (ko) 2021-04-08
TW202011945A (zh) 2020-04-01
AU2013404367A1 (en) 2016-02-18
TWI680774B (zh) 2020-01-01
US20160250232A1 (en) 2016-09-01
US10799515B2 (en) 2020-10-13
CN105555260A (zh) 2016-05-04
IL265381B (en) 2022-05-01
BR122020013726B1 (pt) 2022-11-01
KR102174942B1 (ko) 2020-11-06
EP3542791A1 (en) 2019-09-25
KR20200075041A (ko) 2020-06-25
PH12016500307B1 (en) 2016-05-16
CA2923063A1 (en) 2015-05-07
JP6273356B2 (ja) 2018-01-31
TN2016000119A1 (en) 2017-10-06
NZ717159A (en) 2019-06-28
IL265381A (en) 2019-05-30
MA38847B2 (fr) 2021-02-26
CR20160192A (es) 2016-07-13
IL244260B (en) 2021-08-31
CU20160055A7 (es) 2016-10-28
SG11201600501UA (en) 2016-02-26
TWI736031B (zh) 2021-08-11
AU2013404367B2 (en) 2020-02-27
MA38847A1 (fr) 2017-08-31
EP3062776A1 (en) 2016-09-07
TWI725458B (zh) 2021-04-21
TW201542243A (zh) 2015-11-16
CN105555260B (zh) 2021-04-23
PH12016500307A1 (en) 2016-05-16
SA116370660B1 (ar) 2019-02-24
BR112016004863A8 (pt) 2020-02-11
TW201944984A (zh) 2019-12-01
AU2020201365A1 (en) 2020-03-12
NZ747731A (en) 2020-02-28

Similar Documents

Publication Publication Date Title
UA117260C2 (uk) Лікарський препарат з відстроченим вивільненням
JOP20200148B1 (ar) تركيبة عقار ذو إطلاق متأخر
PH12017502369A1 (en) A delayed release drug formulation
GEP20207119B (en) A delayed release drug formulation
MX2019002162A (es) Formulacion de farmaco de liberacion retardada.
PE20160211A1 (es) Formulacion de farmaco de liberacion retardada
CU24302B1 (es) Formulación de fármaco de liberación retardada